Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL et al..  2024.  Mapping genotypes to chromatin accessibility profiles in single cells.. Nature. 629(8014):1149-1157.

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN et al..  2017.  Ex Vivo CD34-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease a. Biol Blood Marrow Transplant. 23(3):452-458.

Hoban MD, Cost GJ, Mendel MC, Romero Z, Kaufman ML, Joglekar AV, Ho M, Lumaquin D, Gray D, Lill GR et al..  2015.  Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.. Blood. 125(17):2597-604.

Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, Kitchen SG, Zack JA.  2012.  Using the BLT humanized mouse as a stem cell based gene therapy tumor model.. J Vis Exp. (70):e4181.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A et al..  2011.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.. Proc Natl Acad Sci U S A. 108(51):E1408-16.